These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 15199195

  • 1. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
    Hutchison AJ, Speake M, Al-Baaj F.
    Nephrol Dial Transplant; 2004 Jul; 19(7):1902-6. PubMed ID: 15199195
    [Abstract] [Full Text] [Related]

  • 2. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study.
    Al-Baaj F, Speake M, Hutchison AJ.
    Nephrol Dial Transplant; 2005 Apr; 20(4):775-82. PubMed ID: 15703206
    [Abstract] [Full Text] [Related]

  • 3. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
    Joy MS, Finn WF, LAM-302 Study Group.
    Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
    [Abstract] [Full Text] [Related]

  • 4. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
    Chiang SS, Chen JB, Yang WC.
    Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
    [Abstract] [Full Text] [Related]

  • 5. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
    Finn WF, Joy MS, LAM-308 Study Group.
    Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
    [Abstract] [Full Text] [Related]

  • 6. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.
    Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskühler A.
    Nephron Clin Pract; 2006 May; 102(2):c61-71. PubMed ID: 16224198
    [Abstract] [Full Text] [Related]

  • 7. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
    Lee YK, Choi HY, Shin SK, Lee HY.
    Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
    [Abstract] [Full Text] [Related]

  • 8. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T, Lanthanum Carbonate Research Group.
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [Abstract] [Full Text] [Related]

  • 9. Lanthanum carbonate for hyperphosphatemia in patients on peritoneal dialysis.
    Ohno M, Ohashi H, Oda H, Yokoyama H, Okada M, Nagaya M, Izumi K, Ito H, Katoh S.
    Perit Dial Int; 2013 Feb; 33(3):297-303. PubMed ID: 23209037
    [Abstract] [Full Text] [Related]

  • 10. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
    Hutchison AJ, Laville M, SPD405-313 Lanthanum Study Group.
    Nephrol Dial Transplant; 2008 Nov; 23(11):3677-84. PubMed ID: 18577536
    [Abstract] [Full Text] [Related]

  • 11. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
    Shigematsu T, Lanthanum Carbonate Research Group.
    Ther Apher Dial; 2008 Feb; 12(1):55-61. PubMed ID: 18257813
    [Abstract] [Full Text] [Related]

  • 12. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
    Vemuri N, Michelis MF, Matalon A.
    BMC Nephrol; 2011 Sep 30; 12():49. PubMed ID: 21962172
    [Abstract] [Full Text] [Related]

  • 13. Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients.
    Hutchison AJ, Gill M, Copley JB, Poole L, Wilson RJ.
    BMC Nephrol; 2013 Feb 18; 14():40. PubMed ID: 23418668
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
    Finn WF, Joy MS, Hladik G, Lanthanum Study Group.
    Clin Nephrol; 2004 Sep 18; 62(3):193-201. PubMed ID: 15481851
    [Abstract] [Full Text] [Related]

  • 15. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
    Shigematsu T, Lanthanum Carbonate Group.
    Clin Nephrol; 2008 Nov 18; 70(5):404-10. PubMed ID: 19000540
    [Abstract] [Full Text] [Related]

  • 16. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
    Finn WF, SPD 405-307 Lanthanum Study Group.
    Clin Nephrol; 2006 Mar 18; 65(3):191-202. PubMed ID: 16550750
    [Abstract] [Full Text] [Related]

  • 17. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease.
    Freemont AJ, Hoyland JA, Denton J, Lanthanum Carbonate SPD405-303 Study Group.
    Clin Nephrol; 2005 Dec 18; 64(6):428-37. PubMed ID: 16370155
    [Abstract] [Full Text] [Related]

  • 18. Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.
    Curran MP, Robinson DM.
    Drugs; 2009 Nov 12; 69(16):2329-49. PubMed ID: 19852531
    [Abstract] [Full Text] [Related]

  • 19. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate.
    Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A.
    Nephron Clin Pract; 2005 Nov 12; 100(1):c8-19. PubMed ID: 15809508
    [Abstract] [Full Text] [Related]

  • 20. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
    Shigematsu T, Negi S, COLC Research Group.
    Nephrol Dial Transplant; 2012 Mar 12; 27(3):1050-4. PubMed ID: 21771755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.